Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 166.0 | 71 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 128.0 | 68 | ||||
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 78.0 | 53 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 65.0 | 70 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 76.0 | 55 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 180.0 | 73 | |
N2586 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 90.5 | 56 | |
N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 93.0 | 45 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 160.0 | 79 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 88.0 | 67 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 63.5 | 78 | |
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 171.5 | 52 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 80.0 | 73 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 167.0 | 47 | |
N2586 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 96.5 | 62 | |
N2586 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 85.0 | 61 | |
RA2159 | TNF-a | 100 | ng/mL | 1 | MIP-1B | 90.0 | 61 | ||||
RA2159 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 77.0 | 69 | |
RA2159 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 77.0 | 59 | |
RA2159 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 71.0 | 89 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 83.0 | 73 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MIP-1B | 77.0 | 65 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 99.5 | 82 | |
RA2159 | IL-17A | 100 | ng/mL | 1 | MIP-1B | 70.0 | 65 | ||||
N2586 | TNF-a | 100 | ng/mL | 1 | MIP-1B | 89.5 | 66 |